Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion, Inc. (NASDAQ: ACON) is a commercial-stage healthcare technology company focused on chronic low back pain, using Magnetic Resonance Spectroscopy (MRS), biomarkers, and augmented intelligence (AI) algorithms to help physicians identify which lumbar discs may be sources of pain. This news page aggregates updates and announcements related to Aclarion’s business, technology, and clinical programs.
Readers can find coverage of Nociscan, Aclarion’s evidence-supported SaaS platform that noninvasively helps distinguish between painful and nonpainful discs in the lumbar spine. News items often highlight scan volume trends across U.S., U.K., and E.U. sites, payer coverage developments such as private insurer reimbursement in the U.K., and the addition of new imaging centers and physician users. These updates provide context on how Nociscan is being adopted in clinical practice.
A key theme in ACON news is clinical evidence generation. Articles describe the pivotal CLARITY trial, a multi-site randomized study evaluating whether incorporating Nociscan into surgical planning can improve outcomes for patients undergoing surgery for chronic low back pain. Other news discusses real-world evidence publications, including cost-effectiveness analyses and case studies published in journals like the International Journal of Spine Surgery, as well as presentations at scientific meetings such as the International Society of Pain and Neuroscience (ISPN).
Financial and corporate developments also feature prominently. Press releases cover equity financings, cash runway updates, and the company’s debt-free balance sheet, along with leadership appointments in finance and commercial roles. Together, these news items offer investors, clinicians, and other stakeholders a consolidated view of Aclarion’s progress in technology development, market expansion, and clinical validation. Users interested in ACON can monitor this page for ongoing announcements related to Nociscan, CLARITY, payer engagement, and broader corporate milestones.
Aclarion (NASDAQ: ACON) has achieved a significant milestone by securing coverage for its Nociscan technology from Vitality, the third major private health insurer in the UK. This addition means Aclarion now has coverage from 3 of the 4 largest private health insurers in the UK, providing access to nearly 60% of patients with private health insurance in the Greater London market.
Nociscan, a SaaS platform that helps physicians identify the location of chronic low back pain, is gaining traction in the UK healthcare market. The London Clinic, a renowned independent hospital, has played a important role in demonstrating Nociscan's value and securing payer coverage. Aclarion's CEO, Brent Ness, expects this success to be replicated across their 10 KOL sites globally.
With private medical insurance becoming increasingly popular in the UK, these coverage decisions represent a significant shift in Aclarion's business model, providing a clear path to commercialization in the UK market.
Aclarion achieved a significant milestone with Aviva, a top UK private medical insurer, covering Nociscan, its AI-driven diagnostic tool for chronic low back pain. This coverage extends Nociscan's availability to 45% of patients with private insurance in Greater London, joining AXA, which already provides coverage. This development marks a important step in gaining broader market adoption and potential value creation for Aclarion. Nociscan, the first evidence-supported SaaS platform, helps physicians noninvasively identify painful lumbar discs by quantifying chemical biomarkers. The London Clinic is among the premier institutions adopting this technology.
Aclarion (Nasdaq: ACON) announced the first payer coverage of its Nociscan technology by AXA in Greater London, UK, in cooperation with The London Clinic. AXA, the second largest provider of private medical insurance in the UK, covers about 30% of the private medical insurance market with around 3 million insured clients. This endorsement marks a significant milestone for Aclarion, paving the way for widescale commercialization and broader adoption of Nociscan, a tool designed to assist physicians in diagnosing chronic low back pain. The decision is expected to improve patient outcomes significantly and drive future revenue growth for Aclarion.
Aclarion has extended its commercial agreement with The London Clinic to increase the use of Nociscan, a technology that helps identify the location of chronic low back pain. The new contract sets a higher price for Nociscan and includes efforts to secure payer coverage from private health insurers. The London Clinic, a renowned private hospital, will also work to expand access to Nociscan for patients and referring physicians throughout Greater London. The extension follows compelling results from an initial evaluation involving 20 patients. CEO Brent Ness highlighted the importance of the UK market and expressed confidence in achieving similar results in the U.S. market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Aclarion (ACON)?
What is the market cap of Aclarion (ACON)?
